Sky Labs Inc., a leading South Korean healthcare technology company, has entered into a landmark exclusive distribution agreement with Otsuka Pharmaceutical Co., Ltd., one of Japan's most trusted pharmaceutical giants, for the rollout of its innovative ring-type blood pressure monitor, CART BP pro, targeting the hospital and clinic markets across Japan. Announced on February 6, 2026, this partnership builds on a memorandum of understanding signed in December 2024 and represents a strategic open-innovation success story where Sky Labs leveraged its relationship with Korea Otsuka Pharmaceutical to bridge into negotiations with Otsuka's global headquarters.

The CART BP pro device is designed for 24-hour ambulatory blood pressure monitoring (ABPM), addressing critical needs in Japan's massive hypertension patient population, estimated at 43 million individuals. Notably, around 29% of treated patients fail to achieve adequate blood pressure control, while 33% remain undiagnosed, heightening risks of organ damage and cerebrovascular diseases. Abnormal 24-hour blood pressure patterns, particularly nocturnal hypertension, underscore the clinical urgency for precise, continuous monitoring solutions like CART BP pro, which promises to enhance diagnosis, optimize treatment strategies, and enable systematic evaluation of therapeutic outcomes.

Sky Labs' technology has already proven its mettle in the domestic Korean market. Following approval from the Ministry of Food and Drug Safety (MFDS) in 2023, CART BP pro received national health insurance reimbursement in 2024 under the existing medical procedure code for 24-hour ABPM (E6547). This has led to its adoption in over 1,700 medical institutions, including top-tier hospitals, with cumulative prescriptions surpassing 150,000 within just one year of launch. Such robust clinical validation and real-world reliability were pivotal in securing this exclusive Japanese distribution deal, highlighting the device's scalability and trustworthiness for international B2B pharmaceutical technology applications.

Otsuka Pharmaceutical, renowned for its expertise in cardiovascular solutions and extensive distribution networks, will play a crucial role in accelerating CART BP pro's penetration into Japan's healthcare ecosystem. This collaboration aligns with broader trends in Asian pharmaceutical tech, where wearable and remote monitoring devices are transforming chronic disease management, particularly in high-burden areas like hypertension. For pharmaceutical executives and CRO leaders, this deal exemplifies how strategic partnerships can fast-track market entry, leveraging established infrastructure to navigate regulatory landscapes and reimbursement systems in mature markets like Japan.

From a business perspective, the agreement positions Sky Labs to capitalize on Japan's aging population and rising cardiovascular disease prevalence, potentially generating significant revenue streams through B2B sales to hospitals and clinics. It also underscores the growing interoperability between Korean medtech innovations and Japanese pharmaceutical distribution prowess, fostering economic and regional development in the Asian pharma sector. Sky Labs CEO Jack Byunghwan Lee emphasized the company's ambition to validate its blood pressure monitoring technology globally, aiming to lead the industry starting with this Japanese foray.

Founded in 2015, Sky Labs has evolved from atrial fibrillation monitoring with its initial CART device in 2020 to advanced blood pressure solutions, including the consumer-grade CART BP launched in September 2025. This dual-track approach—professional medical devices for institutions and consumer products—diversifies revenue while building brand equity. For manufacturing managers and supply chain professionals, the ring-type form factor introduces efficiencies in production and logistics compared to traditional cuff-based monitors, potentially influencing future pharmaceutical instrumentation and controls standards.

Regulatory compliance remains a cornerstone, with CART BP pro's MFDS approval and HIRA reimbursement setting precedents for similar devices eyeing PMDA (Pharmaceuticals and Medical Devices Agency) clearance in Japan. Procurement teams in Japanese facilities will benefit from Otsuka's vetted supply chain, ensuring quality assurance and validation protocols are met. This deal also signals opportunities in pharmaceutical outsourcing, as Sky Labs expands its platform capabilities, potentially integrating with laboratory instrumentation for data analytics and assay screening in clinical trials.

Looking ahead, the partnership could spur further innovations in cleanroom-compatible wearables and laboratory automation for pharma R&D, aligning with categories like pharmaceutical instrumentation and controls. As Asian pharma tech hubs like Seoul and Tokyo collaborate, deals like this drive contract services growth, enhancing pharmaceutical supply chain solutions and cold chain logistics for device distribution. Overall, this development reinforces Korea's edge in medtech exports, promising sustained B2B value for stakeholders across the region.